Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

MULN Stock Gains Ahead of June 27 Russell 2000 Launch

Today, investors appear to be once again turning bullish on the inclusion of MULN stock in the Russell 2000 and 3000 indices.

SGEN Stock Alert: Is Merck About to Buy Seagen?

Today, various reports have highlighted a potential deal for Merck to buy out Seagen, taking SGEN stock on a nice ride this afternoon.

Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes

Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session.

What Does the 75-Basis-Points Fed Rate Hike Mean for Crypto?

The massive Fed rate hike today will impact the cryptocurrency sector, which is already in a big-time bear market right now.

What Do Higher Interest Rates Mean for Stocks?

Will higher interest rates actually be a good thing for stocks? Let's dive into what the data suggests investors should go from here.